These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 37506197)
1. Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques. Viox EG; Hoang TN; Upadhyay AA; Nchioua R; Hirschenberger M; Strongin Z; Tharp GK; Pino M; Nguyen K; Harper JL; Gagne M; Marciano S; Boddapati AK; Pellegrini KL; Pradhan A; Tisoncik-Go J; Whitmore LS; Karunakaran KA; Roy M; Kirejczyk S; Curran EH; Wallace C; Wood JS; Connor-Stroud F; Voigt EA; Monaco CM; Gordon DE; Kasturi SP; Levit RD; Gale M; Vanderford TH; Silvestri G; Busman-Sahay K; Estes JD; Vaccari M; Douek DC; Sparrer KMJ; Johnson RP; Kirchhoff F; Schreiber G; Bosinger SE; Paiardini M Sci Immunol; 2023 Jul; 8(85):eadg0033. PubMed ID: 37506197 [TBL] [Abstract][Full Text] [Related]
2. Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques. Hoang TN; Viox EG; Upadhyay AA; Strongin Z; Tharp GK; Pino M; Nchioua R; Hirschenberger M; Gagne M; Nguyen K; Harper JL; Marciano S; Boddapati AK; Pellegrini KL; Tisoncik-Go J; Whitmore LS; Karunakaran KA; Roy M; Kirejczyk S; Curran EH; Wallace C; Wood JS; Connor-Stroud F; Kasturi SP; Levit RD; Gale M; Vanderford TH; Silvestri G; Busman-Sahay K; Estes JD; Vaccari M; Douek DC; Sparrer KMJ; Kirchhoff F; Johnson RP; Schreiber G; Bosinger SE; Paiardini M bioRxiv; 2022 Oct; ():. PubMed ID: 36324810 [TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection. Li M; Ayyanathan K; Dittmar M; Miller J; Tapescu I; Lee JS; McGrath ME; Xue Y; Vashee S; Schultz DC; Frieman MB; Cherry S mBio; 2023 Aug; 14(4):e0119423. PubMed ID: 37377442 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells. Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of SARS-CoV-2 by type I and type III interferons. Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093 [TBL] [Abstract][Full Text] [Related]
7. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques. Palesch D; Bosinger SE; Mavigner M; Billingsley JM; Mattingly C; Carnathan DG; Paiardini M; Chahroudi A; Vanderford TH; Silvestri G J Virol; 2018 Jul; 92(14):. PubMed ID: 29720521 [TBL] [Abstract][Full Text] [Related]
8. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR Front Immunol; 2022; 13():888897. PubMed ID: 35663932 [TBL] [Abstract][Full Text] [Related]
9. Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. Singh DK; Aladyeva E; Das S; Singh B; Esaulova E; Swain A; Ahmed M; Cole J; Moodley C; Mehra S; Schlesinger LS; Artyomov MN; Khader SA; Kaushal D Nat Commun; 2022 Feb; 13(1):679. PubMed ID: 35115549 [TBL] [Abstract][Full Text] [Related]
14. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer. Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797 [TBL] [Abstract][Full Text] [Related]
16. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Solimani F; Meier K; Ghoreschi K Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632 [TBL] [Abstract][Full Text] [Related]
18. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. Lokugamage KG; Hage A; de Vries M; Valero-Jimenez AM; Schindewolf C; Dittmann M; Rajsbaum R; Menachery VD J Virol; 2020 Nov; 94(23):. PubMed ID: 32938761 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness? Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304 [TBL] [Abstract][Full Text] [Related]
20. Exacerbated innate host response to SARS-CoV in aged non-human primates. Smits SL; de Lang A; van den Brand JM; Leijten LM; van IJcken WF; Eijkemans MJ; van Amerongen G; Kuiken T; Andeweg AC; Osterhaus AD; Haagmans BL PLoS Pathog; 2010 Feb; 6(2):e1000756. PubMed ID: 20140198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]